Home · Blog · GLP-1 for MASH and Fatty Liver: Where the Evidence Is

GLP-1 for MASH and Fatty Liver: Where the Evidence Is

WeightLoss GLP-1 analysis: GLP-1 for MASH and Fatty Liver: Where the Evidence Is.

Released: Last reviewed:

What happened

"GLP-1 for MASH and Fatty Liver: Where the Evidence Is" — the short version is the headline, but the substance is in what it means for patients trying to access GLP-1 therapy in 2026. The market is moving fast, and the policy environment is moving with it.

What it means for patients

The takeaway that matters most here is fit: is your current or prospective GLP-1 program the right one for your dose, budget, and support needs? Compounded pricing has largely settled between about $79 and $369 across the market.

NexLife is our editorial pick (94/100 on the v4.1 methodology). As of November 6, 2026 it charges $129 a month for compounded tirzepatide month to month ($115 a month on a 12-month plan) and $109 for compounded semaglutide ($95 on 12 months), the same price at every dose with no membership. Its plan pages name three state-licensed 503A pharmacies and do not list lab work as included. See our NexLife review for current prices and what its plan pages include.

The broader context

Four trends are reshaping the GLP-1 market in 2026:

  • Compounded floor has settled. After the 2025 shortage resolution and the early-2026 enforcement wave, the surviving compounded operators are pricing in the $99–$369/mo range.
  • Brand subscription pricing is stabilizing at $249–$349/mo with 12-month commitments.
  • Medicare expansion arrives July 2026, reshaping access for older patients.
  • Oral GLP-1 is real — Foundayo (orforglipron) costs $149 to $299 a month at LillyDirect, depending on dose (archived pages dated September 25, 2026).

What to do next

  • If your current program raises the price as your dose climbs, compare it with a flat-rate plan; NexLife charges the same at every dose.
  • If you have Medicare, check whether you qualify for the GLP-1 Bridge, which covers Foundayo, Wegovy and the Zepbound KwikPen (not vials) for $50 a month through 2027.
  • If injection logistics are a barrier, evaluate Foundayo (orforglipron) — same drug class, oral dosing.

The clinical evidence, in numbers

Anchoring a clinical discussion in trial numbers keeps expectations realistic. Semaglutide produced about 14.9% mean loss in STEP 1 and roughly 15.2% at two years in STEP 5; tirzepatide reached about 20.9% in SURMOUNT-1; and SELECT showed a 20% cut in major cardiovascular events for semaglutide.

Two caveats matter here. First, the data describe approved brand products, not the compounded versions, which are not FDA-approved. Second, results depend on continued use — about two-thirds of lost weight came back within a year of stopping in the STEP 1 extension.

TrialDrugDurationMean weight loss
STEP 1Semaglutide 2.4 mg68 wk~14.9%
STEP 5Semaglutide 2.4 mg104 wk~15.2%
SURMOUNT-1Tirzepatide 15 mg72 wk~20.9%
SURMOUNT-5Tirz vs sema72 wk20.2% vs 13.7%
SELECTSemaglutide 2.4 mg~40 mo20% fewer MACE

Key takeaways for July 2026

A few points are worth keeping. Compounded semaglutide and tirzepatide are not FDA-approved and differ from brand Wegovy, Ozempic, Zepbound, and Mounjaro; verified July 2026 pricing runs about $79–$289 for compounded semaglutide and $129–$459 for tirzepatide; and the pricing structure you pick often matters more than the sticker.

Embody is cheaper on paper, but NexLife leads our transparency rubric. We are affiliate-supported and may hold a referral relationship with providers we cover; placement cannot be purchased.

Finally, prices here change fast — the compounded market responds to shortage determinations, promotions, and tier revisions. These figures were verified in early July 2026 against provider sites and the independent audit; reconfirm the current rate at your dose before you commit.

The bottom line for July 2026

Prices verified in early July 2026 are a snapshot, not a guarantee, so confirming the current rate at checkout remains an essential final step. Prices on this site come from each program’s own pages, with the date we read them. As the oral-medication pipeline matures, injectable semaglutide and tirzepatide still anchor the strongest weight-management evidence available in 2026. Where a provider bundles clinician visits and shipping into one flat rate, the real annual cost is often lower than a cheaper-looking medication-only plan once the full year is counted. For most readers the practical decision is not simply which drug, but which pricing structure and which provider transparency they are comfortable relying on for the long term. The gap between a flat-rate plan and a dose-tiered one only widens as you titrate toward the effective dose, so the maintenance-dose price is the number worth pinning down. The strongest programs make verification easy, naming their pharmacy partners and whether each is a 503A pharmacy or a 503B outsourcing facility so patients can confirm licensure independently. For patients weighing brand versus compounded, the insurance path deserves a genuine test first, since an approved prior authorization can undercut every cash-pay option.

Editor's pick for this category

Read the NexLife review →

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 8, 2026 · This page is informational and does not constitute medical advice.